Novo Pain, Novo Gain (FDA Comes In Clutch With New Approval)

By Stocks News   |   7 months ago   |   Stock Market News
Novo Pain, Novo Gain (FDA Comes In Clutch With New Approval)

Novo didn’t hear no bell…

The Danes will NOT be stopped my friends. Novo Nordisk has been catching hands from every direction for the better part of a year… fired their CEO, axed 9,000 workers, watched their next-gen wonder drug CagriSema eat sh*t in the head-to-head against Eli Lilly's. And yet… they’re STILL coming back for more. More or less.

In short, the FDA just just fast-tracked approval of Wegovy HD (yes, like the TV upgrade)… a cranked-up 7.2-milligram dose of Novo's semaglutide shot. That's 3x the standard 2.4mg dose, and the clinical numbers don't lie: 20.7% average weight loss over 72 weeks, 1 in 3 patients losing 25%+ of their body weight, and 14.1% for patients with Type 2 diabeetus. Oh, and it’s the first drug approved under the FDA's new National Priority Voucher program… in 54 days flat.

This is at BFD because Lilly's Zepbound has been running the table at roughly 22-23% weight loss… a while Novo has putting the “loss” in “Wait, loss”. Meaning, this new dose takes the gap from "embarrassing" to "competitive." Novo's U.S. medical head Dr. Jason Brett said it simply: It really reduces the delta there”. Translation: Tripling your dose was the only answer because the standard one wasn’t cutting it. 

Friendly reminder, Novo needs this W more than they’d admit out loud. The stock is down over 50% from it’s all-time high, while former CEO Lars Fruergaard Jorgensen got the boot last August after eight years.

His replacement Mike Doustdar walked into a company guiding for 5-13% sales DECLINE (in the hottest drug category on the planet) and immediately started handing out pink slips. Meanwhile, Lilly is sitting pretty at 60.5% U.S. market share, guiding $80-83 billion with 25% growth. David Ricks just got CEO of the Year. Novo's guy got a mop. 

But, not all is sunshine and booz for Novo today. Why? Because despite the FDA approval, Novo's semaglutide patent expired in India TODAY… with 40+ generics flooding the market at 90% discounts. One is literally branded "SUNDAE." (Yuge points for the name btw). That said though, Novo isn’t technically cooked. The Wegovy pill already has 400,000+ Americans on it since January. Wegovy HD hits pharmacies in April. And for the first time, Novo's within spitting distance of Lilly's numbers.

Whether any of that matters when Lilly's oral pill drops next month… is anyone's guess. Spoiler: It probably won’t. Until next time, friends… 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer